Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Diffuse Large B-Cell Lymphoma.

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid ...